BPC-157: A Research Overview of the Body Protection Compound

What is BPC-157?

BPC-157 is a synthetic peptide composed of fifteen amino acids, a pentadecapeptide. Its sequence corresponds to a fragment of a protein identified in human gastric juice, and it is frequently described in the literature by the working name "Body Protection Compound." According to PubMed, a 2025 review in Pharmaceuticals characterises it as a stable gastric pentadecapeptide that has shown a range of effects across diverse preclinical models, while noting it has not been approved for use in standard medicine by the FDA or other regulators owing to the absence of sufficient human clinical studies.

It is important to state at the outset what this article is and is not. This is a summary of published laboratory research. BPC-157 is supplied strictly as a research reagent. Nothing here describes use in humans, and none of the findings below have been established in human clinical practice.

Origin and structure

The peptide derives from a sequence found within a larger protein present in the gastric environment. A defining characteristic reported throughout the literature is its stability: it is described as remaining stable in human gastric juice for extended periods, a property that distinguishes it from many peptides that degrade rapidly. This stability is one reason it became a frequent subject of laboratory investigation.

In the research setting, BPC-157 is typically handled as a lyophilised (freeze-dried) powder, reconstituted for experimental use, and characterised by molecular weight and purity via analytical methods such as HPLC and mass spectrometry.

Mechanisms studied in preclinical models

Several mechanisms have been proposed in the experimental literature to account for the effects observed in animal studies. These are research findings in model systems, not established clinical actions.

Angiogenesis and vascular pathways

A recurring theme is an influence on blood-vessel-related processes. Reviews of musculoskeletal soft-tissue studies in rodent models discuss angiogenic activity as a proposed contributor to the tissue responses observed, alongside interactions with growth-factor signalling.

The nitric oxide system

Much of the mechanistic work centres on the nitric oxide (NO) pathway. Reviews describe BPC-157's reported effects being examined in relation to NO synthesis and modulation in animal models, including studies using NO-pathway inhibitors and precursors to probe the interaction.

Cytoprotection

The peptide is frequently framed within the concept of "cytoprotection," the experimental observation, in animal models, of maintained tissue integrity under various challenges. This framing originates with the research groups that have published most extensively on the compound.

The preclinical research landscape

The published body of work spans several tissue systems, and it is worth being precise about what kind of evidence exists. According to PubMed:

A 2019 review in Cell and Tissue Research examined BPC-157 in the context of musculoskeletal soft-tissue healing, covering tendon, ligament and skeletal muscle, and was explicit that the majority of studies had been performed in small rodent models and that efficacy had not been confirmed in humans.

Reviews in Frontiers in Pharmacology (2021) and Biomedicines (2022) summarised experimental work on wound-healing and muscle models respectively, again in rats.

Further reviews have surveyed studies relating to the gastrointestinal tract, the central nervous system, and ocular models, all preclinical.

The consistent pattern across this literature is twofold: reports of broad activity in animal models, and an equally consistent acknowledgement that human clinical evidence is lacking.

Regulatory and research status

This is the most important section for anyone sourcing the compound. According to PubMed, the 2025 Pharmaceuticals review states plainly that BPC-157 has not been approved by the FDA or other global regulatory authorities, citing the absence of comprehensive clinical studies in humans. The same review notes the compound was temporarily prohibited by the World Anti-Doping Agency in 2022, and notes it was not listed as banned at the time of that review.

In the United Kingdom, peptides of this kind are supplied for laboratory research use only. They are not medicines, not licensed for human or veterinary use, and not dietary supplements. Axiom supplies BPC-157 strictly on that basis.

Handling in the research setting

For laboratory users, the practical considerations reported for peptides of this class include storage of the lyophilised material at low temperature, reconstitution with an appropriate solvent for the experiment, and verification of identity and purity against a certificate of analysis. Proper cold storage and minimising freeze-thaw cycles are standard practice for maintaining peptide integrity. (See our handling and storage articles for detail.)

Summary

BPC-157 is a stable pentadecapeptide that has been studied extensively in preclinical models across multiple tissue systems, with proposed mechanisms centring on angiogenesis, the nitric oxide system, and cytoprotection. The evidence base is overwhelmingly animal and in vitro. Human clinical data are absent, and no regulator has approved it for medical use. For researchers, it remains a compound of active scientific interest, and one that should be handled, and discussed, strictly within that research context.